Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RET |
Variant | C630X |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | RET C630X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 630 by a different amino acid. |
Associated Drug Resistance | |
Category Variants Paths |
RET mutant RET C630X |
Transcript | NM_020975.6 |
gDNA | chr10:g.43114488_43114490 |
cDNA | c.1888_1890 |
Protein | p.C630 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406760.1 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_001406759.1 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_020630 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_020630.5 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_020975.6 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_020630.7 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_020975 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_001406743.1 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_020975.5 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
NM_001406744.1 | chr10:g.43114488_43114490 | c.1888_1890 | p.C630 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C630X | medullary thyroid carcinoma | not applicable | N/A | Guideline | Risk Factor | Germline RET C630X mutations result in multiple endocrine neoplasia, type 2A (MEN 2A), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org). | detail... |